Heart shock survival boost? drug tested in critical care
NCT ID NCT07450417
Summary
This study looks back at 418 patients with cardiogenic shock, a life-threatening heart failure emergency. It compares whether starting a drug called empagliflozin early, on top of standard care, helps people survive and stay out of the hospital better than standard care alone. The goal is to see if this approach improves outcomes three months after the shock event.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chru Nancy
Vandœuvre-lès-Nancy, 54500, France
Conditions
Explore the condition pages connected to this study.